ʻSensitizingʼ Test Paradigms: Demographics and Drugs.

§ not interfering with the MOR-antagonist assessments (drugs without administration route stated are i.v.).# 1mg: cold water challenge; 2mg: ischemic pain challenge.A study includes fibromyalgia patients (n = 15, data not reported here).B study includes fibromyalgia patients (n = 10, data not reported here).C study included patients with chronic low back pain (n = 37; data not reported here) and 2 healthy subjects on antidepressant medication.D study includes chronic low back pain patients (n = 45, data not reported here).E study includes treatment arms of combinations of tilidine (100 mg) and naloxone (8–32 mg; data not reported here).F study includes treatment arms with codeine (60 mg p.o.) and codeine/naloxone (2 mg i.v.; data not reported here).G study includes subjects with borderline hypertension (n = 21, data not reported here).H study includes treatment arm with codeine (60 mg p.o.; data not reported here).I study includes patients with bulimia nervosa (n = 10) and anorexia nervosa (n = 10; data not reported here).J study includes patients with major depression (n = 20; data not reported here).K study includes placebo-controlled treatment arm with ketamine (0.4 mg/kg; data not reported here).L the total number of subjects were 20 (4 were excluded).M the total number of subjects were 12 (2 were excluded).N study includes treatment arms with paracetamol (1g i.v.) and paracetamol/naloxone (8 mg i.v.; data not reported here).SD standard deviation.For explanation of abbreviations, please, refer to legend Table 3.ʻSensitizingʼ Test Paradigms: Demographics and Drugs.